Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 4, 2011, Pages 286-295

  Fe Bravo Ortiz, Mara ^a   Gutiérrez Casares, José Ramn ^b   Rodrguez Morales, Alexander ^c   Garca, Mario Alberto Pea ^c   Hidalgo Borrajo, Rebeca ^d  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Psychiatry Department   (Spain)

^c Medical Affairs Department   (Spain)

^d Centro de Salud Mental Infanto juvenil Natividad Zubieta   (Spain)

Author keywords

Caregivers; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DULOXETINE; FLUOXETINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; AMENORRHEA; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; CAREGIVER BURDEN; CATATONIC SCHIZOPHRENIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL STUDY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEBEPHRENIA; HUMAN; HYPERSALIVATION; HYPOTENSION; HYPOTHYROIDISM; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT CARE; PAIN; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIAPISM; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; RESIDUAL SCHIZOPHRENIA; RHABDOMYOLYSIS; SATISFACTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; SPAIN; TREATMENT OUTCOME; UNDIFFERENTIATED SCHIZOPHRENIA; URINE INCONTINENCE;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; CAREGIVERS; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SCHIZOPHRENIA; SPAIN; TREATMENT OUTCOME;

EID: 80053990640     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.608469     Document Type: Article

References (34)

1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-9. (Pubitemid 40343909)
2. Anthony WA. Recovery from mental illness: the guiding vision of the mental health service system in the 1990s. Psychosocial Rehabil J 1993;16:11-23.
3. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 2002;73: 297-311. (Pubitemid 38429494)
4. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997;95:464-8. (Pubitemid 27272195)
5. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9. (Pubitemid 32996037)
6. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004;14:87-92. (Pubitemid 38175425)
7. Llorca PM, Bouhours P, Moreau-Mallet V; French investigators group. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale 2008;34:170-8. (Pubitemid 351621977)
8. Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487-97. (Pubitemid 41127293)
9. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
10. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003; 107(s416):16-23.
11. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)
12. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003;4:222-31. (Pubitemid 37247975)
13. Gort AM, March J, Gó m ez X, de Miguel M, Mazarico S, and Ballest é J. Escala de Zarit reducida en cuidados paliativos. Med Clin (Barcelona) 2005;124:651-3. (Pubitemid 40862976)
14. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65. (Pubitemid 27147597)
15. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 2002;346:16-22. (Pubitemid 34438915)
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209-23. (Pubitemid 41345943)
17. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-15. (Pubitemid 37490235)
18. Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007;90:229-37. (Pubitemid 46177579)
19. Lam Y, Velligan D, DiCocco M. Comparative assessment of antipsychotic adherence by concentration monitoring, pill count and self-report [abstract]. Schizophr Res 2003;60 (Suppl 1):313.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc 1996;276:1253-8. (Pubitemid 26337709)
21. Woods SW, Ziedonis DM, Sernyak MJ, Diaz E, Rosenheck RA. Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr Serv 2000;51:79-84. (Pubitemid 30036753)
22. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51. (Pubitemid 38491171)
23. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand. 2003;107:222-32. (Pubitemid 36250283)
24. Ciudad A, Prieto L, Olivares JM, Montejo AL, Ros S, Novick D; Grupo Espa ñ ol del Estudio SOHO. The European schizophrenia outpatient health outcomes (SOHO) study: baseline fi ndings of the Spanish sample. Actas Esp Psiquiatr 2004;32:227-35. (Pubitemid 39091840)
25. Parellada E, Kouniakis FA, Siurkute A, Schreiner A, Don L. Survey of safety and effi cacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional prospective study. Abstract 89, presented at the European Meet ing of Psychiatry, 24-28 January 2009, Lisbon, Portugal.
26. Moore TA, Covell NH, Essock SM, Miller AL. Real-world antipsychotic treatment practices. Psychiatr Clin North Am 2007;30:401-16. (Pubitemid 47287706)
27. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004;65:531-6.
28. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: effi cacy and safety of the fi rst long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32. (Pubitemid 41070972)
29. Guti é rrez-Maldonado J, Caqueo-Urí zar A, Kavanagh DJ. Burden of care and general health in families of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2005;40:899-904. (Pubitemid 41662419)
30. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980;20:649-55. (Pubitemid 11170845)
31. Ohaeri JU. The burden of caregiving in families with mental illness: a review of 2002. Services research and outcomes. Curr Opin Psychiatry 2003;16:457-465. (Pubitemid 36928492)
32. Han C, Lee BH, Kim YK, Lee HJ, Kim SH, Kim L, et al. Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Prim Care Community Psychiatr 2005;10:118-124.
33. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96 .
34. Prieto L, Sacristá n JA, Hormaechea JA, Casado A, Badia X, G ó mez JC. Psychometric validation of a generic healthrelated quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004;20: 827-35. (Pubitemid 38821519)